Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer

NCT01963481 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01963481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01963481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
October 1, 2017
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic beast cancer